BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI (TEM) to $85 from $75 and keeps a Buy rating on the shares. The firm cites the company’s “strong” Q2 results as revenue topped estimates on 36% growth in data 33% growth in core Tempus genomics revenue, the analyst tells investors in a research note. Tempus AI also indicated it has initiatives in cardiology, radiology, and pathology to run algorithmic diagnostics, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI, Inc.: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
- Mixed options sentiment in tempus AI Inc Class A with shares down 6.85%
- Mixed options sentiment in tempus AI Inc Class A with shares up 3.58%
- tempus AI Inc Class A call volume above normal and directionally bullish
- Buy Rating for Tempus AI, Inc. Driven by Strong Genomics Growth and Promising Outlook